AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
Buy these quality, low-stress stocks for the summer, says Jefferies
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
3 Dividend Aristocrats to Buy in July
The Dividend ETF Quietly Outperforming the S&P 500
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
3 Dividend Stocks to Buy Hand Over Fist in July
AbbVie: Apogee Deal Just Widened An Already Dominant Moat
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Merck, AbbVie probed by US lawmakers over China clinical trials: report
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
3 No-Brainer Dividend Stocks to Buy Right Now
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Lilly, J&J and AbbVie Hit New Highs
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Is AbbVie a Buy After Its Purchase of Apogee?
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
AbbVie's $11 Billion Immunology Bet
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates